Cost-Effectiveness of Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Stroke Prevention
- 1 June 2018
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Stroke
- Vol. 49 (6), 1443-1450
- https://doi.org/10.1161/strokeaha.117.020322
Abstract
Background and Purpose— Percutaneous transcatheter closure of patent foramen ovale (PFO closure) plus antiplatelet therapy has been shown to reduce the risk of recurrent stroke compared with medical therapy alone in carefully selected patients after cryptogenic stroke presumed to be from paradoxical embolism. Our objective was to determine the cost-effectiveness of PFO closure after cryptogenic stroke compared with conservative medical management from a US healthcare payer perspective. Methods— A decision analytic Markov model estimated the 15-year cost and outcomes associated with the additional benefit of PFO closure compared with medical management alone. Model inputs were obtained from published literature, national databases, and a meta-analysis of 5 published randomized clinical trials on PFO closure. Health outcomes were measured in quality-adjusted life years (QALY). Cost-effectiveness used the incremental cost per QALY gained, whereas the net monetary benefit assumed a willingness to pay of $150 000/QALY. One-way and probabilistic sensitivity analyses estimated the uncertainty of model results. Results— At 15 years, PFO closure compared with medical therapy alone improved QALY by 0.33 at a cost saving of $3568, representing an incremental net monetary benefit of $52 761 (95% interval −$8284 to $158 910). When the meta-analysis hazard ratio for stroke was increased to the 95% interval’s upper bound of 0.77, one-way sensitivity analyses suggested that PFO closure’s cost-effectiveness was $458 558 per additional QALY. Probabilistic sensitivity analysis suggested cost-effectiveness in 90% of simulation runs. Conclusions— PFO closure for cryptogenic strokes in the right setting is cost-effective, producing benefit in QALYs gained and potential cost savings. However, patient selection remains vitally important as marginal declines in treatment effectiveness can dramatically affect cost-effectiveness.This publication has 24 references indexed in Scilit:
- Longitudinal Care for Young Adults With StrokeJAMA Neurology, 2017
- Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after StrokeThe New England Journal of Medicine, 2017
- Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after StrokeThe New England Journal of Medicine, 2017
- Cost-Utility Analysis of Mechanical Thrombectomy Using Stent Retrievers in Acute Ischemic StrokeStroke, 2015
- Cost Effectiveness of Percutaneous Closure Versus Medical Therapy for Cryptogenic Stroke in Patients With a Patent Foramen OvaleThe American Journal of Cardiology, 2014
- Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic StrokeThe New England Journal of Medicine, 2013
- Hospitalization Costs for Acute Ischemic Stroke Patients Treated With Intravenous Thrombolysis in the United States Are Substantially Higher Than Medicare PaymentsStroke, 2012
- Functional Outcome 3 Months after Stroke Predicts Long-Term SurvivalCerebrovascular Diseases, 2008
- Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studiesBMJ, 2008
- Infarcts of undetermined cause: The NINCDS stroke data bankAnnals of Neurology, 1989